🔎 Trials Near Me

Akèy › Kolit Ulseratif › Utah

Etid klinik pou Kolit Ulseratif nan Utah

8 etid pou Kolit Ulseratif ap chèche patisipan nan sit nan Utah.

Vil nan Utah

Tèks ofisyèl etid la (Anglè)

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  • Care Access-Ogden, Ogden
  • Advanced Research Institute - South Ogden, Ogden
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT06598943

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  • University of Utah Hospitals & Clinics, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06979336

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • University of Utah, Salt Lake City
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  • Care Access - Ogden, Ogden
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07186101

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • University of Utah Health, Salt Lake City
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 21, 2026 · NCT06095128

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • Velocity Clinical Research, Salt Lake City - Site Number: 8400147, West Jordan
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Aug 20, 2026 · NCT07184996

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  • University of Utah Health, Salt Lake City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT05230173

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

  • Investigational Site Number: 8400007, Ogden
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 23, 2026 · NCT06975722

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.